| Primary information |
|---|
| sequence ID | Seq_5900 |
| Peptide sequence | PEPAKSAPAPK |
| CancerPDF_ID | CancerPDF_ID2235, CancerPDF_ID9772, |
| PMID | 21136997,21533267 |
| Protein Name | Histone H2B type 1-K,Histone H2B type 1-C/E/F/G/I |
| UniprotKB Entry Name | H2B1K_HUMAN,H2B1C_HUMAN |
| Fluid | Serum,Serum |
| M/Z | 1091.59751,546.8 |
| Charge | 1,2 |
| Mass (in Da) | NA,NA |
| fdr | NA,NA |
| Profiling Technique | LC-MS,LC-MS |
| Peptide Identification technique | LC-MS-MS/MS,LC/MS/MS |
| Quantification Technique | LC-ESI-MS,Multiple Reaction Monitoring |
| Labelled/Label Free | Label Free,Label Free |
| FDR | NA,1.49 |
| CancerPDF_ID | CancerPDF_ID2235, CancerPDF_ID9772, |
| p-Value | NA,NA |
| Software | MASCOT(v. 2.2.01),MASCOT |
| Length | 11,11 |
| Cancer Type | Colorectal cancer,Lung adenocarcinoma |
| Database | SwissProt Database,Swissprot Database (57.4) |
| Modification | NA,NA |
| Number of Patients | 30 patients and 30 healthy controls,62 lung adenocarcinoma and 30 healthy control |
| Regulation | NA,"Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" |
| Validation | Leave One out Cross validation,MRM-based validation of 19 candidates |
| Sensitivity | NA,NA |
| Specificity | NA,NA |
| Accuracy | NA,NA |
| Peptide Atlas | PeptideAtlas |
| IEDB | 122512
482896
|